tiprankstipranks
Advertisement
Advertisement
Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
PremiumRatingsBuy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
25d ago
Edgewise Therapeutics falls -9.9%
Premium
The Fly
Edgewise Therapeutics falls -9.9%
25d ago
Video: SpaceX cements $60B Cursor takeover
Premium
The Fly
Video: SpaceX cements $60B Cursor takeover
25d ago
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe FlyActing FDA head vows to block political interference, Endpoint News says
1M ago
Edgewise Therapeutics price target lowered to $48 from $50 at RBC Capital
Premium
The Fly
Edgewise Therapeutics price target lowered to $48 from $50 at RBC Capital
1M ago
Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
Premium
The Fly
Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
1M ago
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
PremiumThe FlyServier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
1M ago
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
Premium
The Fly
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
1M ago
Edgewise Therapeutics confirms sale of sevasemten for up to $2.65B
Premium
The Fly
Edgewise Therapeutics confirms sale of sevasemten for up to $2.65B
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100